IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v27y2009i4p281-297.html
   My bibliography  Save this article

Reviewing the Cost Effectiveness of Rotavirus Vaccination

Author

Listed:
  • Joke Bilcke
  • Philippe Beutels

Abstract

Published health economic evaluations of rotavirus vaccination up until July 2008 were reviewed. We assess whether differences in the results and conclusions of the various studies are due to differences in methodological and modelling choices, and/or the way parameter uncertainty was taken into account, or whether these are merely the result of genuine country/region-specific differences. No unambiguous single answer emerged as to whether universal rotavirus vaccination is or is not cost effective. The relevance and merits of each study need to be assessed within its context. This is illustrated by the fact that comparisons of different analyses for a single country show that one of the most important explanations for the variations in results and conclusions seems to be the use of different information sources for the estimation of input parameters. Future studies should gather reliable and relevant information focusing on the most influential input parameters, i.e. rotavirus mortality (and efficacy against rotavirus deaths) for low- and middle-income countries, and a range of variables for high-income countries, including the incidence and cost of rotavirus hospitalization. Moreover, if no information is available for an important input parameter, the impact of a wide range of values should be explored rather than excluding it from the analysis or specifying a single-point value. Furthermore, future analyses may have to consider ways of accounting for herd immunity (e.g. by using a dynamic model). Copyright Adis Data Information BV 2009

Suggested Citation

  • Joke Bilcke & Philippe Beutels, 2009. "Reviewing the Cost Effectiveness of Rotavirus Vaccination," PharmacoEconomics, Springer, vol. 27(4), pages 281-297, April.
  • Handle: RePEc:spr:pharme:v:27:y:2009:i:4:p:281-297
    DOI: 10.2165/00019053-200927040-00002
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.2165/00019053-200927040-00002
    Download Restriction: Access to full text is restricted to subscribers.

    File URL: https://libkey.io/10.2165/00019053-200927040-00002?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Sun-Young Kim & Sue Goldie, 2008. "Cost-Effectiveness Analyses of Vaccination Programmes," PharmacoEconomics, Springer, vol. 26(3), pages 191-215, March.
    2. H. Melliez & D. Levy-Bruhl & P. Y. Boelle & B. Dervaux & S. Baron & Y. Yazdanpanah, 2008. "Cost and cost-effectiveness of childhood vaccination against rotavirus in France," Post-Print hal-00283456, HAL.
    3. Radboud J. Duintjer Tebbens & Kimberly M. Thompson & M. G. Myriam Hunink & Thomas A. Mazzuchi & Daniel Lewandowski & Dorota Kurowicka & Roger M. Cooke, 2008. "Uncertainty and Sensitivity Analyses of a Dynamic Economic Evaluation Model for Vaccination Programs," Medical Decision Making, , vol. 28(2), pages 182-200, March.
    4. Briggs, Andrew & Sculpher, Mark & Claxton, Karl, 2006. "Decision Modelling for Health Economic Evaluation," OUP Catalogue, Oxford University Press, number 9780198526629.
    5. Nancy Thiry & Philippe Beutels & Pierre Damme & Eddy Doorslaer, 2003. "Economic Evaluations of Varicella Vaccination Programmes," PharmacoEconomics, Springer, vol. 21(1), pages 13-38, January.
    6. M. Brisson & W. J. Edmunds, 2006. "Impact of Model, Methodological, and Parameter Uncertainty in the Economic Analysis of Vaccination Programs," Medical Decision Making, , vol. 26(5), pages 434-446, September.
    7. Mark A. Miller & Laura McCann, 2000. "Policy analysis of the use of hepatitis B, Haemophilus influenzae type b‐, Streptococcus pneumoniae‐conjugate and rotavirus vaccines in national immunization schedules," Health Economics, John Wiley & Sons, Ltd., vol. 9(1), pages 19-35, January.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Marisa Holubar & Maria Christina Stavroulakis & Yvonne Maldonado & John P A Ioannidis & Despina Contopoulos-Ioannidis, 2017. "Impact of vaccine herd-protection effects in cost-effectiveness analyses of childhood vaccinations. A quantitative comparative analysis," PLOS ONE, Public Library of Science, vol. 12(3), pages 1-22, March.
    2. Stefanie Knoll & Christoph Mair & Ursula Benter & Katja Vouk & Baudouin Standaert, 2013. "Will vaccination against rotavirus infection with RIX4414 be cost-saving in Germany?," Health Economics Review, Springer, vol. 3(1), pages 1-11, December.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Anna K. Lugnér & Sido D. Mylius & Jacco Wallinga, 2010. "Dynamic versus static models in cost‐effectiveness analyses of anti‐viral drug therapy to mitigate an influenza pandemic," Health Economics, John Wiley & Sons, Ltd., vol. 19(5), pages 518-531, May.
    2. Sun-Young Kim & Sue Goldie, 2008. "Cost-Effectiveness Analyses of Vaccination Programmes," PharmacoEconomics, Springer, vol. 26(3), pages 191-215, March.
    3. Andrija S Grustam & Nasuh Buyukkaramikli & Ron Koymans & Hubertus J M Vrijhoef & Johan L Severens, 2019. "Value of information analysis in telehealth for chronic heart failure management," PLOS ONE, Public Library of Science, vol. 14(6), pages 1-23, June.
    4. Greg Plosker, 2011. "Rotavirus Vaccine RIX4414 (Rotarix™)," PharmacoEconomics, Springer, vol. 29(11), pages 989-1009, November.
    5. Marina Antoniou & Céu Mateus & Bruce Hollingsworth & Andrew Titman, 2024. "A Systematic Review of Methodologies Used in Models of the Treatment of Diabetes Mellitus," PharmacoEconomics, Springer, vol. 42(1), pages 19-40, January.
    6. Chiranjeev Sanyal & Don Husereau, 2020. "Systematic Review of Economic Evaluations of Services Provided by Community Pharmacists," Applied Health Economics and Health Policy, Springer, vol. 18(3), pages 375-392, June.
    7. Mark Oppe & Daniela Ortín-Sulbarán & Carlos Vila Silván & Anabel Estévez-Carrillo & Juan M. Ramos-Goñi, 2021. "Cost-effectiveness of adding Sativex® spray to spasticity care in Belgium: using bootstrapping instead of Monte Carlo simulation for probabilistic sensitivity analyses," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(5), pages 711-721, July.
    8. Kaitlyn Hastings & Clara Marquina & Jedidiah Morton & Dina Abushanab & Danielle Berkovic & Stella Talic & Ella Zomer & Danny Liew & Zanfina Ademi, 2022. "Projected New-Onset Cardiovascular Disease by Socioeconomic Group in Australia," PharmacoEconomics, Springer, vol. 40(4), pages 449-460, April.
    9. Andrea Marcellusi & Raffaella Viti & Loreta A. Kondili & Stefano Rosato & Stefano Vella & Francesco Saverio Mennini, 2019. "Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data," PharmacoEconomics, Springer, vol. 37(2), pages 255-266, February.
    10. Risha Gidwani & Louise B. Russell, 2020. "Estimating Transition Probabilities from Published Evidence: A Tutorial for Decision Modelers," PharmacoEconomics, Springer, vol. 38(11), pages 1153-1164, November.
    11. Joseph F. Levy & Marjorie A. Rosenberg, 2019. "A Latent Class Approach to Modeling Trajectories of Health Care Cost in Pediatric Cystic Fibrosis," Medical Decision Making, , vol. 39(5), pages 593-604, July.
    12. Qi Cao & Erik Buskens & Hans L. Hillege & Tiny Jaarsma & Maarten Postma & Douwe Postmus, 2019. "Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical exploration," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(3), pages 475-482, April.
    13. Jorge Luis García & James J. Heckman, 2021. "Early childhood education and life‐cycle health," Health Economics, John Wiley & Sons, Ltd., vol. 30(S1), pages 119-141, November.
    14. Tushar Srivastava & Nicholas R. Latimer & Paul Tappenden, 2021. "Estimation of Transition Probabilities for State-Transition Models: A Review of NICE Appraisals," PharmacoEconomics, Springer, vol. 39(8), pages 869-878, August.
    15. Eleanor Heather & Katherine Payne & Mark Harrison & Deborah Symmons, 2014. "Including Adverse Drug Events in Economic Evaluations of Anti-Tumour Necrosis Factor-α Drugs for Adult Rheumatoid Arthritis: A Systematic Review of Economic Decision Analytic Models," PharmacoEconomics, Springer, vol. 32(2), pages 109-134, February.
    16. Manuel Gomes & Robert Aldridge & Peter Wylie & James Bell & Owen Epstein, 2013. "Cost-Effectiveness Analysis of 3-D Computerized Tomography Colonography Versus Optical Colonoscopy for Imaging Symptomatic Gastroenterology Patients," Applied Health Economics and Health Policy, Springer, vol. 11(2), pages 107-117, April.
    17. Isaac Corro Ramos & Maureen P. M. H. Rutten-van Mölken & Maiwenn J. Al, 2013. "The Role of Value-of-Information Analysis in a Health Care Research Priority Setting," Medical Decision Making, , vol. 33(4), pages 472-489, May.
    18. Wei Fang & Zhenru Wang & Michael B. Giles & Chris H. Jackson & Nicky J. Welton & Christophe Andrieu & Howard Thom, 2022. "Multilevel and Quasi Monte Carlo Methods for the Calculation of the Expected Value of Partial Perfect Information," Medical Decision Making, , vol. 42(2), pages 168-181, February.
    19. Martin Hoyle, 2008. "Future Drug Prices and Cost-Effectiveness Analyses," PharmacoEconomics, Springer, vol. 26(7), pages 589-602, July.
    20. Bauer, Annette & Knapp, Martin & Alvi, Mohsin & Chaudhry, Nasim & Gregoire, Alain & Malik, Abid & Sikander, Siham & Tayyaba, Kiran & Wagas, Ahmed & Husain, Nusrat, 2024. "Economic costs of perinatal depression and anxiety in a lower-middle income country: Pakistan," LSE Research Online Documents on Economics 122650, London School of Economics and Political Science, LSE Library.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:27:y:2009:i:4:p:281-297. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.